Federation des caisses Desjardins du Quebec’s Avadel Pharmaceuticals AVDL Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20	Closed	-$134	–	2457
2020 Q4	$134	Hold	20	–	–	﹤0.01%	2302
2020 Q3	$101	Hold	20	–	–	﹤0.01%	2134
2020 Q2	$162	Hold	20	–	–	﹤0.01%	2071
2020 Q1	$159	Buy	+20	New	+$154	﹤0.01%	2171
2019 Q3	–	Sell	-28,941	Closed	-$83.5K	–	2280
2019 Q2	$83.5K	Hold	28,941	–	–	﹤0.01%	1350
2019 Q1	$41.7K	Hold	28,941	–	–	﹤0.01%	1368
2018 Q4	$74.8K	Hold	28,941	–	–	﹤0.01%	1199
2018 Q3	$127K	Hold	28,941	–	–	﹤0.01%	1126
2018 Q2	$178K	Hold	28,941	–	–	﹤0.01%	1060
2018 Q1	$211K	Hold	28,941	–	–	﹤0.01%	1003
2017 Q4	$237K	Hold	28,941	–	–	﹤0.01%	996
2017 Q3	$305K	Hold	28,941	–	–	﹤0.01%	910
2017 Q2	$319K	Buy	28,941 +4,994	+21%	+$50.1K	0.01%	844
2017 Q1	$232K	Buy	+23,947	New	+$239K	﹤0.01%	871

Other funds holding AVDL

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ACM

Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's AVDL Position: Q1 2021 in Review

Federation des caisses Desjardins du Quebec sold out of Avadel Pharmaceuticals (AVDL) in Q1 2021, closing a stake of 20 shares — an estimated $134 sold.

Federation des caisses Desjardins du Quebec first reported a position in AVDL in Q1 2017 and held it in 14 quarters. The position peaked at $319K in Q2 2017. 76 funds tracked by Wall St. Rank hold AVDL as of Q1 2021.

Federation des caisses Desjardins du Quebec reported no remaining Avadel Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 20 Avadel Pharmaceuticals shares in Q1 2021, an estimated $134.
Federation des caisses Desjardins du Quebec first reported a position in Avadel Pharmaceuticals in Q1 2017 and held it in 14 quarters.
Federation des caisses Desjardins du Quebec's Avadel Pharmaceuticals position peaked at $319K in Q2 2017.
76 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2021.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2021, filed 30 Aug 2024.